Sign In
Buy MESO
$14.52
+0 (+0%)
At Close: Jun 03, 2026
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Mesoblast Limited (MESO) Investigation
08:00pm, Monday, 17'th Aug 2020
NEW YORK, NY / ACCESSWIRE / August 17, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mesoblast Limited (‘Mesoblast" or the "Company") (NASDAQ
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mesoblast Limited
MESO EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Mesoblast Limited – MESO
06:47pm, Sunday, 16'th Aug 2020
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Mesoblast Limited (NASDAQ: MESO) resulting from allegations th
Mesoblast Gets Favorable Votes From FDA Committee for Ryoncil
05:53pm, Friday, 14'th Aug 2020
Mesoblast (MESO) gets ODAC's vote in the ratio of 9:1 for GVHD drug.
5 Stock Gainers for Friday: Dillard's, Intrepid Potash, Suzano SA
05:41pm, Friday, 14'th Aug 2020
Intrepid Potash, Suzano SA, Mesoblast, Farfetched and Dillard's are among Friday's top gainers.
Why Mesoblast's Stock is Trading Higher Today
03:02pm, Friday, 14'th Aug 2020
Mesoblast (NASDAQ: MESO) shares are trading higher after the company announced the Oncologic Drugs Advisory Committee of the FDA voted in favor of its RYONCIL for efficacy in children with steroid-ref
TG Therapeutics Umbralisib Development, And Other News: The Good, Bad And Ugly Of Biopharma
12:57pm, Friday, 14'th Aug 2020
TG Therapeutics reports development for Umbralisib. Mesoblast gets FDA nod for Ryoncil.
NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the Oncologic Drugs Advisory C
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO
01:57am, Friday, 14'th Aug 2020
Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors are advised to contact Robert S. Willoughby at newaction
Mesoblast Tanks 35% Ahead Of FDA Meeting; Analyst Sees 85% Stock Upside
11:51am, Wednesday, 12'th Aug 2020
Australian biotech Mesoblast sank 35% on Tuesday ahead of this week’s US Federal Drug Administration (FDA) committee meeting, which will assess the efficacy of its flagship stem cell therapy candida
Mesoblast Plunges as FDA Questions Cell-Therapy Manufacturing
06:46pm, Tuesday, 11'th Aug 2020
The Australian stem-cell company will face some pointed questions from regulators about how it manufactures stem cells.
Update on Scheduled FDA Advisory Committee Meeting
10:00am, Tuesday, 11'th Aug 2020
NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today provided an update on the scheduled meeting of the Oncologic Drugs Advisory Committee (ODAC) of the United St
Kamada: Under-The-Radar COVID-19 Therapy Play With Downside Protection And Margin Of Safety
10:51am, Wednesday, 22'nd Jul 2020
US and global pharma companies that are working on credible COVID-19 treatments are up massively YTD, often more than 100% and far surpassing performance of general pharma indices.
NEW YORK, July 21, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the Oncologic Drugs Advisory Committee (ODAC) of the United States Food and Drug.
Mesoblast Solving Unmet Medical Needs Including Severe ARDS Caused By COVID-19
01:20pm, Friday, 17'th Jul 2020
MESO has been approved to sell remestemcel-l (labeled TEMCELL by partner JCR Pharmaceuticals) for acute Graft vs Host disease (aGVHD) in Japan for several years.
